Major Depression. Severe depressive episode without psychotic symptoms
Conditions
Interventions
Intervention 1: Case group will receive Serteralin (200 mg/d) + Celexibe (200 mg BID) for 6 weeks. Intervention 2: Control group will receive Serteralin (200 mg/d) + Placebo for 6 weeks.
Placebo
Case group will receive Serteralin (200 mg/d) + Celexibe (200 mg BID) for 6 weeks.
Control group will receive Serteralin (200 mg/d) + Placebo for 6 weeks
Sponsors
National Iranian Oil Company Health Organization
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1. Major Depression according to DSM IV and Hamilton Depression Scale(HamD) 2. 18 y 50 y Exclusion Criteria: 1. Having psychotic disorders 2. Receiving anti-depressant drugs during last month 3. Receiving ECT during last two months 4. Having thyroid disorder 5. Having Cardiovascular disorders 6. Pregnancy 7. Breast Feeding 8. Age 50 y
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Antidepressants and Celxocibe side effects. Timepoint: 0, 2, 4 and 6 weeks intervals. Method of measurement: drug side effects check list. | — |
Primary
| Measure | Time frame |
|---|---|
| Depression. Timepoint: 0, 2, 4, 6 weeks intervals. Method of measurement: Hamilton depression scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProfessor Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed